We are live on ! Find out more
NAGE

Niagen Bioscience

78 hedge funds and large institutions have $45.1M invested in Niagen Bioscience in 2024 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 21 increasing their positions, 15 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more call options, than puts

Call options by funds: $379K | Put options by funds: $173K

75% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 16

40% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 15

16% more funds holding

Funds holding: 6778 (+11)

4.45% more ownership

Funds ownership: 17.43%21.88% (+4.4%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

1% less capital invested

Capital invested by funds: $45.7M → $45.1M (-$560K)

Holders
78
Holders Change
+11
Holders Change %
+16.42%
% of All Funds
1.13%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
28
Increased
21
Reduced
15
Closed
16
Calls
$379K
Puts
$173K
Net Calls
+$206K
Net Calls Change
-$48K

NAGE Hedge Fund Activity: Q2 2024 in Review

78 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q2 2024, worth a combined $45.1M — down 1.2% from $45.7M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new NAGE positions and 16 closed out — a net gain of 12 holders — while 21 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $7.41M. The largest seller was Millennium Management, cutting an estimated $1.31M.

  • 78 institutional investors held Niagen Bioscience (NAGE) as of Q2 2024, up from 67 in Q1 2024.
  • Funds reported $45.1M of Niagen Bioscience stock for Q2 2024, down 1.2% quarter-over-quarter.
  • 28 funds opened new Niagen Bioscience positions in Q2 2024 and 16 closed out, a net change of +12 holders.
  • The largest Niagen Bioscience buyer in Q2 2024 was BlackRock, an estimated $7.41M added.
  • The largest Niagen Bioscience seller in Q2 2024 was Millennium Management, an estimated $1.31M sold.

Based on aggregated 13F filings for Q2 2024.